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Background: Myocardial infarction (MI) is frequently followed by left ventricular
(LV) remodeling, heart failure and increased long-term morbidity and mortality.
Parachute Ventricular Partitioning Device offers an additional strategy to medical
therapy with exclusion of the infarcted wall to decrease end diastolic volumes, thereby
decreasing myocardial work and wall stress and to receive an immediate hemody-
namic beneﬁt as well as a better clinical outcome. Before and after the implantation,
invasive hemodynamic measurements (including right heart study) were performed in
all patients to evaluate the acute hemodynamic changes.
Methods:We implanted the Parachute device in 8 patients between September 2012
and March 2013 who had a prior myocardial infarction with an apical aneurysm and
abnormal wall motion. All procedures were done percutaneous via the right femoral
artery. Invasive hemodynamic measurements were taken before and after device
implantation in all patients.
Results: Implantation was successful in all patients, except dislocation of the device
from the proper landing zone requiring removal with a snare from the left ventricle.
The remaining 7 patients showed a signiﬁcant increase in three parameters: stroke
volume (SV), cardiac output (CO) and cardiac index (CI). The SV had an average
increase in 35.9% (+ 14.6 ml). Also the CO had an increase in 30.5% (+ 0.8 l/min)
while the CI increased by 32.3% (+ 0.5 l/min/m2). Heart rate, pulmonary capillary
wedge pressure, mean pulmonary arterial pressure and right atrial pressure remained
essentially unchanged. No vascular complications and no other adverse events
occurred during the hospital course in all patients.
Conclusions: The data demonstrate the feasibility and acute hemodynamic efﬁcacy of
percutaneous LV partitioning in congestive heart failure with a prior anterior MI.
Implantation of a Parachute device resulted in an immediate reduction in LV
volumes and an increase in LV ejection fraction prooﬁng the concept of device
efﬁcacy in this speciﬁc patient population.S
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Background: Early mechanical circulatory support with a percutaneous ventricular
assist device may improve outcome. However, the optimal timing to initiate hemo-
dynamic support to achieve maximal beneﬁts has not been well characterized. We
aimed to evaluate the periprocedural characteristics and outcomes of patients with an
acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) who
received hemodynamic support with Impella 2.5 prior to their percutaneous coronary
intervention (Pre-PCI) compared to those who received support following their PCI
(Post-PCI).
Methods: A total of 154 consecutive patients from 38 U.S. hospitals participating in
the USpella Registry were included in the present analysis. The primary endpoint was
survival to discharge. Secondary endpoints included the assessment of hemodynamics
and in-hospital complications. Independent predictors for mortality were also
identiﬁed.
Results: Patients in the Pre-PCI group had a higher prevalence of diabetes (p¼0.015),
peripheral vascular disease (p¼0.008), chronic obstructive pulmonary disease
(p¼0.047), prior stroke (p¼0.043) and extensive revascularization with more lesions
(p¼0.006) and vessels (p¼0.01) treated when compared to the Post-PCI group. The
incidence of in-hospital complications was similar between the two groups. At
discharge, patients in the Pre-PCI group had signiﬁcantly better survival (65.1%)
compared with patients in the Post-PCI group (40.7%) (p¼0.003). Survival in the
Pre-PCI group remained favourable in subgroup analysis. In multivariate logistic
regression analysis, the institution of hemodynamic support prior to the PCI was an
independent predictor of in-hospital survival (Odds ratio for mortality 0.37, 95%
conﬁdence interval: 0.17-0.79, p¼0.011).
Conclusions: In patients with AMI complicated by CS, the institution of hemody-
namic support with Impella 2.5 prior to PCI is associated with a more complete
revascularization and improved survival.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-445
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Background: PROTECT II demonstrated a trend of improved outcomes in patients
with impaired LVEF and left main or 3-vessel disease (3VD) undergoing PCI with
hemodynamic support using Impella 2.5 (IR2.5) or intra-aortic balloon pump (IABP).
However, it is unclear if this trend was due to a speciﬁc beneﬁt in a patient
subpopulation, or if certain patients may derive particular beneﬁt from PCI with IR2.5
support. We therefore evaluated the efﬁcacy of the IR2.5 vs. IABP in the PROTECT II
study exclusively in patients with 3-vessel coronary disease.
Methods: For this pre-speciﬁed analysis, patients in PROTECT II were stratiﬁed upon
enrollment into the left main or 3VD subgroups and then randomized to IR2.5 or
IABP. Patients enrolled in the 3VD substrata were required to have LVEF 30%. We
evaluated the 30- and 90-day outcomes among the 3VD group (n¼325, IR2.5 167,
IABP 158).
Results: The groups were well matched, except for prior CABG and symptomatic
heart failure, which were more common in the IR2.5 group (both p0.01). Patients
were at high risk for adverse outcomes, with mean risk scores for IR2.5 vs. IABP,
including Additive EuroScore 8.4  3.6 v 8.3  3.6 (p¼0.73), STS morbidity and
mortality 27.1  14.4 v 29.5  15.6 (p¼0.15), respectively. The mean number of
lesions treated was 3.0  1.5 vs. 2.9  1.4 (p¼0.61). While on a per-pt basis
rotational atherectomy use was similar between groups (12.6% vs. 9.5%, p¼0.38),
the number of passes per pt and per lesion was higher in the IR2.5 group (both
p<0.005). At 30 days after PCI with IR2.5 or IABP, patients that received IR2.5
support trended toward reduction in the primary outcome of incidence of major
adverse events (MAE): 32.9% vs. 42.4% (p¼0.078). At 90 days after PCI there was
a signiﬁcant difference favoring IR2.5 for incidence of MAE was 39.5% vs. 51.0%
(p¼0.039).
Conclusions: Patients with 3VD and reduced LVEF show improved outcomes at 90
days when PCI was performed using the IR2.5 hemodynamic support device.TCT-446
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Background: To compare the outcome of percutaneous coronary intervention (PCI)
treatment with intra-aortic balloon counterpulsation (IABP) versus PCI without IABP
on 30-days survival in patients with cardiogenic shock (CS) due to acute coronary
syndromes (STEMI and non-STEMI).
Methods: We extracted data for all consecutive patients with CS undergoing PCI due
to STEMI between 2005 and 2013 from the Swedish Coronary Angiography and
Angioplasty Registry (SCAAR) for ﬁve hospitals in western county of Sweden
(Västra Götaland). Cox proportional–hazards regression adjusted for propensity score
was used to compare the groups in regard to 30-days mortality. The following vari-
ables were used to calculate propensity score: age, gender, smoking habits, hyper-
tension, hyperlipidaemia, diabetes, previous PCI, previous infarction, previous
CABG, antiplatelet therapy, gpIIbIIIa, bivalirudin, severity of coronary disease,
complete revascularization, success.
Results: In total, there were 390 consecutive CS patients treated with IABP (n¼213)
or without IABP (n¼177) between 2005 and 2013. After adjustment with propensity
score, the baseline characteristics of the two groups were well balanced. Treatment
with IABP was not associated with lower 30-days mortality (HR 0.86; 95% CI 0.61-
1.21).
Conclusions: In this observational study the treatment with IABP during primary PCI
in patients with CS due to STEMI was not associated with a more favorable outcome
as compared with primary PCI without IABP.acts/POSTER/Circulatory Support, Heart Failure, and HOCM B137
